Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares
October 21 2016 - 8:31AM
Business Wire
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical
company, announced that the underwriters for its public offering of
3,750,000 shares of its common stock at $40.00 per share have
elected to exercise in full their option to purchase up to an
additional 562,500 shares of common stock at the public offering
price, less the underwriting discounts and commissions. The closing
for the additional purchase of 562,500 shares is expected to take
place concurrently with the closing for the initial purchase of
3,750,000 shares on October 25, 2016, subject to customary closing
conditions.
Citigroup and J.P. Morgan are acting as lead book-running
managers, Credit Suisse is acting as joint book-running manager and
BofA Merrill Lynch is acting as lead manager for the offering.
Stifel is acting as co-manager for the offering.
The offering is being made pursuant to an automatically
effective shelf registration statement filed with the Securities
and Exchange Commission (SEC) on January 20, 2015. A prospectus
supplement describing the terms of the offering has been filed with
the SEC and is available on the SEC’s website at www.sec.gov.
Copies of the prospectus supplement and the accompanying prospectus
relating to the offering may also be obtained by contacting
Citigroup Global Markets Inc., c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, or by phone at (800)
831-9146; J.P. Morgan Securities LLC, Attention: Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, New York
11717, or by phone at (866) 803-9204; or Credit Suisse, Attention:
Prospectus Department, One Madison Avenue, New York, NY 10010, by
telephone at (800) 221-1037, or by email at
newyork.prospectus@credit-suisse.com.
This news release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or other jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
other jurisdiction.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161021005221/en/
Puma Biotechnology, Inc.Alan H. Auerbach or Mariann
Ohanesian424-248-6500info@pumabiotechnology.comir@pumabiotechnology.com
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Apr 2023 to Apr 2024